[´Ý±â X]

ȸ»ç¼Ò°³ ±¤°í¹®ÀÇ Áñ°Üã±â
·Î±×ÀΠȸ¿ø°¡ÀÔ ID/PWã±â
ȸ»ç¼Ò°³ °í°´¼¾ÅÍ ±¤°í¾È³» ȸ¿ø¾à°ü °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ û¼Ò³âº¸È£Á¤Ã¥
 06¿ù 02ÀÏ (±Ý) 18:36 ÁÖ¿ä´º½º
¸íÀÇŽ¹æ ½ÅÁ¦Ç°Á¤º¸ ¿À´ÃÀǵ¿Á¤ µ¥½ºÅ©Ä®·³ Ä¿¹Â´ÏƼ ±¸ÀÎ ±¸Á÷
Current Medical Issue
87 Regression of Liver Fibrosis after Biliary Drainage in Patients.. IEM 2009/03/27
85 Natural History of Multiple Sclerosis with Childhood Onset (.. IEM 2009/03/27
84 Neostigmine for the Treatment of Acute Colonic Pseudo-Obstructi.. IEM 2009/03/27
83 Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hy.. IEM 2009/03/27
82 Vasopressin and Epinephrine vs. Epinephrine Alone in Cardiopulm.. IEM 2009/03/27
79 Effect of a Multifactorial Intervention on Mortality in Type 2 .. IEM 2009/03/27
 1 | 2 | 3 
 ¹Ú¹Ì¿¬ ´ëÇÑ¿©µå¸§ÁÖ»ç..
¡°¿©µå¸§¿¡ ¹Î°£¿ä¹ýÀº À§
 ¼ÛÁ¤ÇÑ ºÐ´ç¼­¿ï´ëº´¿øÀå
 ¹Ú Á¤¿õ °¡Ãµ´ë ±æº´¿ø..
´ë¿õ¹ÙÀÌ¿À, SGLT-2 ¾ïÁ¦Á¦ 'º£..
´ç´¢º´ Ä¡·áÁ¦ ¶óÀξ÷ °­È­, ȯÀÚ ¼±ÅÃ±Ç È®´ë¿Í »îÀÇ Áú °³¼±¿¡ ±â¿© ´ë¿õ¹ÙÀÌ¿À°¡ SGLT-2 ¾ïÁ¦Á¦..
¡ºOECD º¸°ÇÅë°è 2022¡»·Î º¸´Â ¿ì¸®³ª¶ó º¸..
Á¦5Â÷ ±¹¹Îº¸°ÇÀÇ·á½ÇÅÂÁ¶»ç °á°ú
»óº´ ¼ö´ç ½Ã¹ü»ç¾÷
'¼ö¼ú½Ç CCTV ¼³Ä¡' ³í¶õ
"źźÇÑ °¨¿°º´ ´ëÀÀ ü°è °®Ãç¾ß"
¡°ÀûÁ¤ ¼ö°¡ ±â¹Ý °³¿øÈ¯°æ °³¼± Àý½Ç¡±